STOP-COVID19 trial to test novel bronchiectasis treatment

Respiratory researchers in the UK are launching a trial to test a novel treatment for inflammatory lung conditions in hospitalised Covid-19 patients. Brensocatib, a reversible inhibitor of dipeptidyl peptidase 1 (DPP1) currently being developed by biopharmaceutical company Insmed, will be tested in 300 patients across 10 UK sites after recent positive results in in adult ...

Already a member?

Login to keep reading.

© 2021 the limbic